المؤلفون: Lubberink M, Direcks W, Emmering J, van Tinteren H, Hoekstra OS, van der Hoeven JJ, Molthoff CF, Lammertsma AA, Lubberink, Mark, Direcks, Wieteke, Emmering, Jasper, van Tinteren, Harm, Hoekstra, Otto S, van der Hoeven, Jacobus J, Molthoff, Carla F M, Lammertsma, Adriaan A

المصدر: Molecular Imaging & Biology; Dec2012, Vol. 14 Issue 6, p777-782, 6p

المؤلفون: Horlings HM, van Laar RK, Kerst JM, Helgason HH, Wesseling J, van der Hoeven JJ, Warmoes MO, Floore A, Witteveen A, Lahti-Domenici J, Glas AM, Van't Veer LJ, de Jong D

المصدر: Journal of Clinical Oncology; 9/20/2008, Vol. 26 Issue 27, p4435-4441, 7p

المؤلفون: de Groot S, Gelderblom H, Fiocco M, Bovée JVMG, van der Hoeven JJM, Pijl H, Kroep JR

المصدر: OncoTargets and Therapy, Vol Volume 10, Pp 2963-2970 (2017)

مصطلحات موضوعية: Ewing sarcoma, chemotherapy, IGF-1, IGF-2, IGF-BP3, IGF-1R, survival, biomarkers, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.dovepress.com/serum-levels-of-igf-1-and-igf-bp3-are-associated-with-event-free-survi-peer-reviewed-article-OTT; https://doaj.org/toc/1178-6930

URL الوصول: https://doaj.org/article/16a7544561724f02ae47318314e2eef7

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Samsom KG; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Schipper LJ; Department of Molecular Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Office Jaarbeurs Innovation Mile (JIM), Utrecht, The Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, The Netherlands., Bosch LJ; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Lalezari F; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Klompenhouwer EG; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., de Langen AJ; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Buffart TE; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Riethorst I; Hartwig Medical Foundation, Amsterdam, The Netherlands., Schoenmaker L; Hartwig Medical Foundation, Amsterdam, The Netherlands., Schout D; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Berg JG; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., de Bruijn E; Hartwig Medical Foundation, Amsterdam, The Netherlands., van der Hoeven JJ; Hartwig Medical Foundation, Amsterdam, The Netherlands., van Snellenberg H; Hartwig Medical Foundation, Amsterdam, The Netherlands., van der Kolk LE; Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, The Netherlands., Cuppen E; Oncode Institute, Office Jaarbeurs Innovation Mile (JIM), Utrecht, The Netherlands.; Hartwig Medical Foundation, Amsterdam, The Netherlands.; Center for Molecular Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands., Voest EE; Department of Molecular Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Office Jaarbeurs Innovation Mile (JIM), Utrecht, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Meijer GA; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Monkhorst K; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

المصدر: The Journal of pathology [J Pathol] 2022 Oct; Vol. 258 (2), pp. 179-188. Date of Electronic Publication: 2022 Aug 03.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: John Wiley And Sons Country of Publication: England NLM ID: 0204634 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-9896 (Electronic) Linking ISSN: 00223417 NLM ISO Abbreviation: J Pathol Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms*/diagnosis , Neoplasms*/genetics, Feasibility Studies ; Genomics/methods ; Humans ; United Kingdom ; Whole Genome Sequencing/methods

المؤلفون: van Uden DJP; Department of Surgery, Rijnstate Hospital, Wagnerlaan 55, 6815 AD, Arnhem, the Netherlands. Electronic address: djpvanuden@gmail.com., van Maaren MC; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Hoog Catharijne, Godebaldkwartier 419, 3511 DT, Utrecht, the Netherlands; Department of Health Technology and Services Research, Technical Medical Center, University of Twente, Drienerlolaan 5, 7522 NB, Enschede, the Netherlands., Strobbe LJA; Department of Surgery, Canisius Wilhelmina Hospital, Weg Door Jonkerbos 100, 6532 SZ, Nijmegen, the Netherlands., Bult P; Department of Pathology, Radboud University Medical Center Nijmegen, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, the Netherlands., Stam MR; Radiotherapy Group, Wagnerlaan 47, 6815 AD, Arnhem, the Netherlands., van der Hoeven JJ; Department of Medical Oncology, Radboud University Medical Center Nijmegen, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, the Netherlands., Siesling S; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Hoog Catharijne, Godebaldkwartier 419, 3511 DT, Utrecht, the Netherlands; Department of Health Technology and Services Research, Technical Medical Center, University of Twente, Drienerlolaan 5, 7522 NB, Enschede, the Netherlands., de Wilt JHW; Department of Surgical Oncology, Radboud University Medical Center Nijmegen, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, the Netherlands., Blanken-Peeters CFJM; Department of Surgery, Rijnstate Hospital, Wagnerlaan 55, 6815 AD, Arnhem, the Netherlands.

المصدر: Surgical oncology [Surg Oncol] 2020 Jun; Vol. 33, pp. 43-50. Date of Electronic Publication: 2020 Jan 10.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 9208188 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-3320 (Electronic) Linking ISSN: 09607404 NLM ISO Abbreviation: Surg Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Radiotherapy*, Antineoplastic Agents/*therapeutic use , Carcinoma/*therapy , Inflammatory Breast Neoplasms/*therapy , Mastectomy/*methods, Aged ; Antineoplastic Agents, Hormonal ; Antineoplastic Agents, Immunological ; Axilla ; Bone Neoplasms/secondary ; Bone Neoplasms/therapy ; Carcinoma/secondary ; Female ; Humans ; Inflammatory Breast Neoplasms/pathology ; Liver Neoplasms/secondary ; Liver Neoplasms/therapy ; Lung Neoplasms/secondary ; Lung Neoplasms/therapy ; Lymph Node Excision/methods ; Mastectomy, Segmental/methods ; Middle Aged ; Multivariate Analysis ; Neoplasm Staging ; Netherlands ; Propensity Score ; Proportional Hazards Models ; Survival Rate

المؤلفون: van Uden DJP; Department of Surgery, Radboud University Medical Center Nijmegen, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands. djpvanuden@gmail.com., van Maaren MC; Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Hoog Catharijne, Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands.; Department of Health Technology and Services Research, University of Twente, Drienerlolaan 5, 7522 NB, Enschede, The Netherlands., Strobbe LJA; Department of Surgery, Canisius Wilhelmina Hospital, Weg door Jonkerbos 100, 6532 SZ, Nijmegen, The Netherlands., Bult P; Department of Pathology, Radboud University Medical Center Nijmegen, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands., van der Hoeven JJ; Department of Medical Oncology, Radboud University Medical Center Nijmegen, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands., Siesling S; Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Hoog Catharijne, Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands.; Department of Health Technology and Services Research, University of Twente, Drienerlolaan 5, 7522 NB, Enschede, The Netherlands., de Wilt JHW; Department of Surgery, Radboud University Medical Center Nijmegen, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands., Blanken-Peeters CFJM; Department of Surgery, Rijnstate Hospital, Wagnerlaan 55, 6815 AD, Arnhem, The Netherlands.

المصدر: Breast cancer research : BCR [Breast Cancer Res] 2019 Oct 17; Vol. 21 (1), pp. 113. Date of Electronic Publication: 2019 Oct 17.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 100927353 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-542X (Electronic) Linking ISSN: 14655411 NLM ISO Abbreviation: Breast Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Inflammatory Breast Neoplasms/*pathology , Receptor, ErbB-2/*metabolism , Receptors, Estrogen/*metabolism , Receptors, Progesterone/*metabolism, Aged ; Bone Neoplasms/metabolism ; Bone Neoplasms/secondary ; Bone Neoplasms/therapy ; Female ; Humans ; Inflammatory Breast Neoplasms/metabolism ; Inflammatory Breast Neoplasms/therapy ; Kaplan-Meier Estimate ; Liver Neoplasms/metabolism ; Liver Neoplasms/secondary ; Liver Neoplasms/therapy ; Lung Neoplasms/metabolism ; Lung Neoplasms/secondary ; Lung Neoplasms/therapy ; Middle Aged ; Neoplasm Staging ; Netherlands ; Prognosis

المؤلفون: de Groot S; Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands. Electronic address: degroot@imta.eur.nl., van der Linden N; Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands., Franken MG; Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands., Blommestein HM; Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands., Leeneman B; Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands., van Rooijen E; Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands., Koos van der Hoeven JJ; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands., Wouters MW; Dutch Institute for Clinical Auditing (DICA), Leiden, The Netherlands; Netherlands Cancer Institute, Amsterdam, The Netherlands., Westgeest HM; Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; Department of Oncology, Amphia Hospital, Breda, The Netherlands., Uyl-de Groot CA; Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands; Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.

المصدر: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2017 Apr; Vol. 20 (4), pp. 627-636. Date of Electronic Publication: 2016 Apr 06.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 100883818 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1524-4733 (Electronic) Linking ISSN: 10983015 NLM ISO Abbreviation: Value Health Subsets: MEDLINE

مواضيع طبية MeSH: Decision Making* , Policy Making* , Registries*/standards, Data Collection/*methods , Health Services Research/*methods , Medical Oncology/*methods, Confidentiality ; Data Accuracy ; Data Collection/economics ; Data Collection/standards ; Guideline Adherence ; Guidelines as Topic ; Health Services Research/economics ; Health Services Research/standards ; Humans ; Medical Oncology/economics ; Medical Oncology/standards ; Netherlands ; Organizational Objectives ; Pharmacovigilance ; Reproducibility of Results ; Research Support as Topic

المؤلفون: Schneider TC; Departments of Clinical Oncology.; Pathology, and., de Wit D; Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands., Links TP; Department of Endocrinology, University Medical Center Groningen, University of Groningen, 9713 GZ, The Netherlands; and., van Erp NP; Department of Clinical Pharmacy, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands., van der Hoeven JJ; Departments of Clinical Oncology., Gelderblom H; Departments of Clinical Oncology., Roozen IC; Departments of Clinical Oncology., Bos M; Departments of Clinical Oncology., Corver WE; Pathology, and., van Wezel T; Pathology, and., Smit JW; Department of Clinical Pharmacy, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands., Morreau H; Pathology, and., Guchelaar HJ; Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands., Kapiteijn E; Departments of Clinical Oncology.

المصدر: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2017 Feb 01; Vol. 102 (2), pp. 698-707.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study

بيانات الدورية: Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375362 Publication Model: Print Cited Medium: Internet ISSN: 1945-7197 (Electronic) Linking ISSN: 0021972X NLM ISO Abbreviation: J Clin Endocrinol Metab Subsets: MEDLINE

مواضيع طبية MeSH: Outcome Assessment, Health Care*, Adenocarcinoma, Follicular/*drug therapy , Antineoplastic Agents/*pharmacology , Everolimus/*pharmacology , Thyroid Neoplasms/*drug therapy, Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Everolimus/administration & dosage ; Everolimus/adverse effects ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged

SCR Disease Name: Thyroid cancer, follicular

المؤلفون: Jochems A; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands., Schouwenburg MG; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands., Leeneman B; Institute for Medical Technology Assessment, Erasmus University, Burgemeester Oudlaan 50, 3062 PA, Rotterdam, The Netherlands., Franken MG; Institute for Medical Technology Assessment, Erasmus University, Burgemeester Oudlaan 50, 3062 PA, Rotterdam, The Netherlands., van den Eertwegh AJ; Department of Medical Oncology, VU University Medical Centre, De Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands., Haanen JB; Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands., Uyl-de Groot CA; Institute for Medical Technology Assessment, Erasmus University, Burgemeester Oudlaan 50, 3062 PA, Rotterdam, The Netherlands., Aarts MJ; Department of Medical Oncology, Maastricht University Medical Centre, P. Debyelaan 25, 6229 HX, Maastricht, The Netherlands., van den Berkmortel FW; Department of Internal Medicine, Zuyderland Medical Centre Heerlen-Sittard, Henri Dunantstraat 5, 6419 PC, Heerlen, The Netherlands., Blokx WA; Department of Pathology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands., Cardous-Ubbink MC; Netherlands Comprehensive Cancer Organisation, Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands., Groenewegen G; Department of Medical Oncology, University Medical Centre Utrecht, Heidelberglaan 100, 3582, CX, Utrecht, The Netherlands., de Groot JW; Department of Medical Oncology, Isala, Dokter van Heesweg 2, 8025 AB, Zwolle, The Netherlands., Hospers GA; Department of Medical Oncology, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands., Koornstra RH; Department of Medical Oncology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands., Kruit WH; Department of Medical Oncology, Erasmus MC Cancer Institute, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands., Louwman MW; Netherlands Comprehensive Cancer Organisation, Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands., Piersma D; Department of Internal Medicine, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ, Enschede, The Netherlands., van Rijn RS; Department of Internal Medicine, Medical Centre Leeuwarden, Henri Dunantweg 2, 8934 AD, Leeuwarden, The Netherlands., Ten Tije AJ; Department of Internal Medicine, Amphia Hospital, Molengracht 21, 4818 CK, Breda, The Netherlands., Vreugdenhil G; Department of Internal Medicine, Maxima Medical Centre, De Run 4600, 5504 DB, Eindhoven, The Netherlands., Wouters MW; Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., van der Hoeven JJ; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. Electronic address: J.J.M.van_der_Hoeven@lumc.nl.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2017 Feb; Vol. 72, pp. 156-165. Date of Electronic Publication: 2016 Dec 25.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Registries*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Melanoma/*drug therapy , Protein Kinase Inhibitors/*therapeutic use , Quality Assurance, Health Care/*methods , Skin Neoplasms/*drug therapy, Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cancer Care Facilities/standards ; Clinical Audit/methods ; Cost-Benefit Analysis ; Female ; Humans ; Male ; Melanoma/secondary ; Middle Aged ; Netherlands ; Protein Kinase Inhibitors/adverse effects ; Quality of Health Care ; Quality of Life ; Survival Analysis